{
  "drug_name": "Tocilizumab",
  "url": "https://wikem.org/wiki/Tocilizumab",
  "scraped_at": "2026-01-10T08:03:46.919551",
  "sections": {
    "Administration": {
      "text": "Type: IL-6 antagonist\nDosage Forms:\nRoutes of Administration:\nCommon Trade Names:",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adult_Dosing": {
      "text": "",
      "subsections": {
        "COVID": {
          "text": "8 mg/kg actual body weight (up to 800 mg) administered as a single IV dose",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "COVID": {
      "text": "8 mg/kg actual body weight (up to 800 mg) administered as a single IV dose",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Special_Populations": {
      "text": "",
      "subsections": {
        "Renal_Dosing": {
          "text": "Adult:\nPediatric:",
          "tables": []
        },
        "Hepatic_Dosing": {
          "text": "Adult:\nPediatric:",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Pregnancy_Rating": {
      "text": "",
      "subsections": {
        "Renal_Dosing": {
          "text": "Adult:\nPediatric:",
          "tables": []
        },
        "Hepatic_Dosing": {
          "text": "Adult:\nPediatric:",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Lactation_risk": {
      "text": "",
      "subsections": {
        "Renal_Dosing": {
          "text": "Adult:\nPediatric:",
          "tables": []
        },
        "Hepatic_Dosing": {
          "text": "Adult:\nPediatric:",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Renal_Dosing": {
      "text": "Adult:\nPediatric:",
      "subsections": {
        "Hepatic_Dosing": {
          "text": "Adult:\nPediatric:",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Hepatic_Dosing": {
      "text": "Adult:\nPediatric:",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Contraindications": {
      "text": "Allergy to class/drug",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Pharmacology": {
      "text": "Half-life:\nMetabolism:\nExcretion:",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Comments": {
      "text": "Trials show that may improved survival and other clinical outcomes in patients in admitted severe disease\nIn clinical trials, a third of the participants received a second dose of tocilizumab 8 hours after the first dose if no clinical improvement was observed.",
      "subsections": {},
      "tables": [],
      "links": []
    }
  }
}